MultiStem

Phase 3Small molecule

MultiStem is one of 205 small molecule programs targeting Systemic Inflammatory Response Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

204

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Inflammatory Response SyndromeActive, not recruiting

Liver TransplantActive, not recruiting

StrokeActive, not recruiting

COVID-19Active, not recruiting

Acute Respiratory Distress SyndromeActive, not recruiting

Myeloid LeukemiaActive, not recruiting

Ischemic StrokeActive, not recruiting

Systemic Inflammatory Response SyndromePhase 2

Active, not recruiting

Liver TransplantPhase 1

Active, not recruiting

StrokePhase 3

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

Acute Respiratory Distress SyndromePhase 1/Phase 2

Active, not recruiting

Myeloid LeukemiaPhase 1

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

MultiStem

HHealios K.K.

Phase 3

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Transplant1 trial

Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation

Terminated·PProf. Dr. Marc-H. Dahlke, Ph. D.·Phase 1·NCT01841632·3 enrolled

Systemic Inflammatory Response Syndrome1 trial

MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Recruiting·HHealios K.K.·Phase 2·NCT04533464·156 enrolled

Myeloid Leukemia1 trial

Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

Completed·HHealios K.K.·Phase 1·NCT00677859·36 enrolled

Ischemic stroke1 trial

Study to Examine the Effects of MultiStem in Ischemic Stroke

Completed·HHealios K.K.·Phase 2·NCT01436487·134 enrolled

Stroke1 trial

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study

Unknown status·HHealios K.K.·Phase 3·NCT03545607·300 enrolled

2 more indications

Acute Respiratory Distress Syndrome1 trial

A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome

Completed·HHealios K.K.·Phase 1/2·NCT02611609·36 enrolled

COVID-191 trial

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

Unknown status·HHealios K.K.·Phase 2/3·NCT04367077·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for MultiStem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MultiStem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MultiStem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Healios K.K. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHealios K.K.

MultiStem

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Transplant1 trial

Systemic Inflammatory Response Syndrome1 trial

Myeloid Leukemia1 trial

Ischemic stroke1 trial

Stroke1 trial

Acute Respiratory Distress Syndrome1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News